Genitourinary Cancer and Molecular Profiling

The GU Cancer Channel on VJOncology is supported by Exelixis These supporters have no influence over the production of the content.

View overview page
1:03
Clinical subtyping of cancer from blood based on comprehensive epigenomic profiling
Federica Di Nicolantonio • 22 Oct 2023
1:44
Positive biomarkers to select patients for bladder preservation in bladder cancer
Andrea Necchi • 23 Oct 2023
1:18
CLIMATE: miR-371a-3p as a biomarker in post-orchiectomy testicular cancer
Ciara Conduit • 6 Jul 2023
0:46
CTC HOXB13 RNA in mCRPC: abiraterone/enzalutamide impact
Andrew J. Armstrong • 3 Jun 2023
1:44
Immune checkpoint inhibitors in mCRPC
Pedro Barata • 5 Jun 2023
2:57
Efficacy of sacituzumab govitecan in mUC by Trop-2 expression
Scott Tagawa • 3 Jun 2023
1:51
Future directions in the field of targeted therapies for urothelial carcinoma
Scott Tagawa • 3 Jun 2023
1:05
Future endeavours with ADCs in bladder cancer
Yohann Loriot • 5 Jun 2023
0:58
ADCs in the management of urothelial carcinoma
Yohann Loriot • 5 Jun 2023
1:23
CDH1-mutated clinically advanced urothelial bladder cancer: real-world clinical outcome study
Philippe Spiess • 10 Mar 2023
3:47
PARP inhibitors for metastatic hormone sensitive prostate cancer
Bertrand Tombal • 17 Mar 2023
1:38
From conventional to molecular diagnostics for prostate cancer
Eva Compérat • 7 Mar 2023
2:26
Managing biochemical relapse after radical prostatectomy
Juan Gómez Rivas • 16 Mar 2023
5:41
Diagnosing and treating castration resistant prostate cancer
Juan Gómez Rivas • 16 Mar 2023
2:36
Innovation and care in the next 12 months for prostate cancer
Eva Compérat • 7 Mar 2023
1:45
Results from dataset analysis of CDH1-mutated urothelial carcinoma patients
Andrea Necchi • 18 Feb 2023

The GU Cancer Channel on VJOncology is supported by Exelixis

These supporters have no influence over the production of the content.

The content of VJOncology is intended for healthcare professionals